Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib in Relapsed/Refractory Multiple Myeloma
NCT01351623Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2011
- Primary completion
- Jan 2016
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Best Overall Response Rate at 2 years. Started May 2011; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01351623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01351623.